EUCTR2020-000713-32-FR进行中（未招募）1 期
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 267
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Key Inclusion Criteria:
- •AL amyloidosis stage IIIa based on the 2013 European Modification of the 2004 Standard Mayo Clinic Staging in patients with advanced cardiac involvement at the time of Screening
- •Measurable hematologic disease at Screening as defined by at least one of the following:
- •Involved/uninvolved free light chain difference (dFLC) > 4 mg/dL or
- •Involved free light chain (iFLC) > 4 mg/dL with abnormal ratio or
- •Serum protein electrophoresis (SPEP) m-spike > 0.5 g/dL
- •Histopathological diagnosis of amyloidosis based on polarizing light microscopy of green bi-refringent material in Congo red stained tissue specimens AND confirmation of AL derived amyloid deposits by at least one of the following:
- •Immunohistochemistry or
- •Mass spectrometry or
- •Characteristic electron microscopy appearance
- •Cardiac involvement as defined by:
- •Documented clinical signs and symptoms supportive of a diagnosis of heart failure in the setting of a confirmed diagnosis of AL
- •amyloidosis in the absence of an alternative explanation for heart failure
- •At least one of the following:
- •Endomyocardial biopsy demonstrating AL cardiac amyloidosis or
- •Echocardiogram demonstrating a mean left ventricular wall thickness > 12 mm at diastole in the absence of other causes
- •(e.g., severe hypertension, aortic stenosis), which would adequately explain the degree of wall thickening or
- •Cardiac magnetic resonance imaging (MRI) with gadolinium contrast agent diagnostic of cardiac amyloidosis
- •Planned first-line treatment for plasma cell dyscrasia is cyclophosphamide-bortezomib-dexamethasone (CyBorD) administered as SoC.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 160
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 107
排除标准
- •Key Exclusion Criteria:
- •Have any other form of amyloidosis other than AL amyloidosis
- •Received prior therapy for AL amyloidosis or multiple myeloma. A maximum exposure of 160 mg dexamethasone (or equivalent corticosteroid) since diagnosis of AL amyloidosis and prior to randomization is allowed.
- •Meets the International Myeloma Working Group (IMWG) definition of multiple myeloma or POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes) (Appendix A)
- •Have supine systolic blood pressure < 90 mmHg or symptomatic orthostatic hypotension, defined as a decrease in systolic blood pressure upon standing of > 30 mmHg despite medical management (e.g., midodrine, fludrocortisones) in the absence of volume depletion.
研究者
相似试验
进行中（未招募）
1 期
A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis.stage IIIb cardiac AL amyloidosisMedDRA version: 20.0Level: PTClassification code 10007509Term: Cardiac amyloidosisSystem Organ Class: 10007541 - Cardiac disordersEUCTR2019-004254-28-BECaelum Biosciences, Inc.111
招募中
3 期
A Phase 3 Study to Evaluate the Efficacy and Safety of CAEL-101 in Plasma Cell Dyscrasia Treatment Naive Patients with Mayo Stage IIIa AL AmyloidosisAL AmyloidosisJPRN-jRCT2031200300Caelum Medical Monitor9
进行中（未招募）
1 期
A study of Baricitinib in patients with LupusEUCTR2017-005028-11-NLEli Lilly and Company1,100
招募中
3 期
A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis2022-503073-11-00Alexion Pharmaceuticals Inc.56
进行中（未招募）
1 期
A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis.stage IIIb cardiac AL amyloidosisMedDRA version: 20.0Level: PTClassification code 10007509Term: Cardiac amyloidosisSystem Organ Class: 10007541 - Cardiac disordersEUCTR2019-004254-28-NLAlexion Pharmaceuticals, Inc.124